[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fever\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fever":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,53,83,116,146,175,207,237,259,280,304,329,354,379,410,434,465,492,521,543],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":4,"leadSponsor":49,"locationsCount":52},"100054419","familial-mediterranean-fever-and-related-disorders-genetics-and-disease-characteristics-100054419",false,"NCT00001373","Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics","An Exploratory Study of the Genetics, Pathophysiology, and Natural History of Autoinflammatory Diseases","* INCLUSION CRITERIA:\n\nThere are three populations that will be included in this study: subjects with known or suspected autoinflammatory diseases, family members of subjects with known or suspected autoinflammatory diseases, and healthy controls. Persons interested in participation may be given a screening questionnaire to determine eligibility. Questions in the screening questionnaire are important to help us determine if subjects have known autoinflammatory diseases, or if there is a high clinical suspicion of autoinflammatory disease.\n\nIn order to be eligible to participate in this study as a subject with known or suspected autoinflammatory disease, an individual must meet all of the following criteria:\n\n1. Stated willingness to participate in study procedures (which at the very least includes providing a mail-in sample for genetic analysis);\n2. Regardless of gender, at least one month of age;\n3. A medical history that, in the expert opinion of the study team, is consistent with the possibility of autoinflammatory disease; and\n4. Ability of the subject, parents (in the case of children), or Legally Authorized Representative to understand and the willingness to sign a written informed consent document.\n\nIn order to be eligible to participate in this study as a family member of a subject with known or suspected autoinflammatory disease, an individual must meet all of the following criteria:\n\n1. Stated willingness to participate in study procedures (which at the very least includes providing a mail-in sample for genetic analysis);\n2. Regardless of gender, at least one month of age;\n3. Relationship, either by blood or marriage, to an individual enrolled or about to be enrolled in the study with known or suspected autoinflammatory disease;\n4. Likelihood, in the expert opinion of the study team, that analysis of a sample from the individual would advance genetic or functional analysis of the affected relative's possible autoinflammatory condition; and\n5. Ability of the subject, parents (in the case of children), or Legally Authorized Representative to understand and the willingness to sign a written informed consent document.\n\nIn order to be eligible to participate in this study as a healthy volunteer, an individual must meet all of the following criteria:\n\n1. Stated willingness to participate in study procedures for healthy volunteers;\n2. Regardless of gender, at least one year old, and not pregnant (by history of a missed menstrual period);\n3. Likelihood, in the expert opinion of the study team, that a sample from the individual would advance the functional analysis of an autoinflammatory condition under study; and\n4. Ability of the subject or parents (in the case of children) to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nFor any of the three categories of subjects, an individual will be excluded from participation in this study if he or she has a medical condition that would, in the opinion of the investigators, confuse the interpretation of the study.",true,"ALL","2 Months","115 Years",{"count":21,"type":22},5000,"ESTIMATED","OBSERVATIONAL","This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases.\n\nThe following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.\n\nPatients will undergo a medical and family history, physical examination, blood and urine tests. Additional tests and procedures may include the following:\n\n1. X-rays\n2. Consultations with specialists\n3. DNA sample collection (blood or saliva sample) for genetic studies. These might include studies of specific genes, or more complete sequencing of the genome.\n4. Additional blood samples a maximum of 1 pint (450 ml) during a 6-week period for studies of white cell adhesion (stickiness)\n5. Leukapheresis for collecting larger amounts of white cells for study. For this procedure, whole blood is collected through a needle in an arm vein. The blood flows through a machine that separates it into its components. The white cells are removed and the rest of the blood is returned to the body through another needle in the other arm.\n\nPatients may be followed approximately every 6 months to monitor symptoms, adjust medicine dosages, and undergo routine blood and urine tests. They will receive genetic counseling by the study team on the risk of having affected children and be advised of treatment options.\n\nParticipating relatives will undergo a medical and family history, possibly with a review of medical records, physical examination, blood and urine tests. Additional procedures may include a 24-hour urine collection, X-rays, and consultations with medical specialists. A DNA sample (blood or saliva) will also be collected for genetic studies. Additional blood samples of no more than 550 mL during an 8-week period may be requested for studies of white cell adhesion (stickiness).\n\nRelatives who have familial Mediterranean fever, TRAPS, or hyper-IgD syndrome will receive the same follow-up and counseling as described for patients above.\n\nNormal volunteers and patients with gout will have a brief health interview and check of vital signs (blood pressure and pulse) and will provide a blood sample (up to 90 ml, or 6 tablespoons). Additional blood samples of no more than 1 pint over a 6-week period may be requested in the future....",[26,27,28,29,30,31,32],"Familial Mediterranean Fever (FMF)","Autoinflammation","Periodic Fever","Fever","Genetic Diseases","ROSAH","ALPK1",[34,35,28,36,37,38,39,27,40,41],"Splenomegaly","Retinal Dystrophy","Optic Nerve Edema","HEADACHE","Genetics","Familial Mediterranean","Anhidrosis","Alpha-Kinase 1","RECRUITING","2026-06-27",{"date":45,"type":46},"2026-06-30","ACTUAL",{"date":48,"type":46},"1994-03-10",{"name":50,"class":51},"National Human Genome Research Institute (NHGRI)","NIH",5,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":70,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100586073","optimizing-the-care-pathway-of-febrile-children-via-capillary-c-reactive-protein-assay-in-primary-care-100586073","NCT06910631","Optimizing the Care Pathway of Febrile Children Via Capillary C-reactive Protein Assay in Primary Care","Optimisation du Parcours de Soins Des Enfants fébriles Par l'Utilisation de la CRP Capillaire en Soins Primaires : Protocole d'un Essai Multicentrique randomisé","CRP-CAP","Inclusion Criteria:\n\n* The patient must be a member or beneficiary of a health insurance plan\n* Children consulting primary health institutes with fever (temperature ≥ 38°C) requiring CRP testing:\n\n  * Fever \\> 12h in infants aged 3 to 6 months\n  * Fever ≥ 5 days in children over 6 months of age\n  * Fever \\>12h regardless of age, and at the time of consultation, the doctor is concerned about the child's general condition, the tolerance of the fever, or doubts about a bacterial focus (e.g. suspicion of pneumopathy, appendicitis, etc.).\n* No severity criteria necessitating immediate hospitalization\n* No bacterial infection whose diagnosis is exclusively clinical or identified by other means (e.g. purulent AOM, bacterial angina identified by RDT, etc.).\n* Child whose parents and child have been informed about the study, and at least one parent has given consent for their child's participation in the study.\n* Enrolment of the child according to their capacity of discernment (for children aged 12 and over, enrolment is essential).\n* Child affiliated to or benefiting from a health insurance scheme\n\nExclusion Criteria:\n\n* The subject is participating in a category 1 interventional study, or a study with drug or medical device\n* Premature infants under one year of age\n* Immunosuppression\n* Sunstroke\n* Chronic infection\n* Malignant pathology\n* Autoimmune pathology\n* Sickle cell disease\n* Child with a central catheter","3 Months","15 Years",{"count":64,"type":22},420,"INTERVENTIONAL",[67],"NA","Fever is the leading reason for outpatient consultations among children aged 2 to 9 years. The main concern in fever is severe bacterial infection, particularly for younger children. History and clinical examination do not always differentiate viral infections from bacterial infection. In 20% of febrile children, no infectious focus is found after examination and additional tests are necessary. The first one is measuring C-reactive protein (CRP). The results are obtained in several hours on an outpatient basis, causing long delays before starting treatment and often requiring telephone calls or further consultations. Emergency room use is constantly increasing, generating growing tensions within healthcare facilities, yet a large number of visits are avoidable. Among children visiting the pediatric emergency room, parents reported being referred by their primary care physician in approximately 20% of cases for children aged 1 to 5 years and in 30% of cases for children under one year old. The use of capillary medical device to measure CRP in primary care could reduce this referral rate and help relieve overcrowding in emergency rooms, as well as unscheduled consultation centers and medical analysis laboratories. This would result in a streamlined care pathway, saving time for both physicians and patients, as well as reducing the cost of care for the healthcare system.",[29],[71],"C-reactive protein","2026-06-19",{"date":74,"type":46},"2026-06-23",{"date":76,"type":46},"2025-09-15",{"date":78,"type":22},"2027-06",{"name":80,"class":81},"Centre Hospitalier Universitaire de Nīmes","OTHER",37,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":16,"sex":17,"minAge":91,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":94,"conditions":95,"keywords":101,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":115},"100637454","biomedical-signal-extraction-from-symptom-descriptions-an-observational-registry-using-the-opengenome-platform-100637454","NCT07578610","Biomedical Signal Extraction From Symptom Descriptions: An Observational Registry Using the OpenGenome Platform","Accuracy and Calibration of Evidence-Grounded Biomedical Signal Extraction From Free-Text Symptom Descriptions: A Prospective Observational Registry Using the OpenGenome Automated Research Instrument","OGNOME-REG","* Automated or programmatically generated submissions detected by rate limiting\n* Submissions containing no discernible symptom or health-related content","18 Years",{"count":93,"type":22},1000,"This registry prospectively collects anonymized free-text symptom descriptions submitted voluntarily by adults through the OpenGenome platform at opengenome.bio. For each submission, the system retrieves real biomedical literature from PubMed and ClinicalTrials.gov in parallel, applies a constrained reasoning model operating under a strict output schema, and returns a structured biological signal report. The study evaluates the internal consistency of extracted signals, the calibration of confidence scores relative to dataset size and symptom specificity, and the distribution of biological signal categories across a large anonymous population. No intervention is assigned. No participant contact occurs. All data is anonymized at the point of collection.",[96,29,97,98,99,100],"Signs and Symptoms","Myalgia","Skin Diseases","Hemorrhagic Fever With Renal Syndrome","Zoonoses",[102,103,104],"biomedical signal extraction","symptom analysis","PubMed","2026-05-16",{"date":107,"type":46},"2026-05-19",{"date":109,"type":46},"2026-05-05",{"date":111,"type":22},"2028-05-30",{"name":113,"class":114},"OpenGenome","NETWORK",1,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":16,"sex":17,"minAge":123,"maxAge":61,"enrollmentInfo":124,"targetDuration":4,"studyType":65,"phases":126,"briefSummary":127,"conditions":128,"keywords":131,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":115},"100629122","viromes-in-infants-presenting-with-a-septic-syndrome-100629122","NCT07470541","Viromes in Infants Presenting With a Septic Syndrome","V-NOURSSE","Inclusion criteria :\n\nFor participants :\n\n* Age \\\u003C 3 months\n* Fever ≥38°C confirmed in pediatric emergency department\n\nFor control group :\n\n* Age \\\u003C 3 months\n* Children requiring general anesthesia or managed in the pediatric emergency department, or during hospitalization or consultation, for a non-infectious condition requiring venipuncture\n\nExclusion criteria :\n\nFor participants :\n\n* Lack of parental\u002Flegal guardian consent\n* Lack of affiliation with a social security scheme\n* Antibiotic treatment within 8 days prior to inclusion\n\nFor control group :\n\n* Lack of parental\u002Flegal guardian consent\n* Lack of affiliation with a social security scheme\n* Antibiotic treatment within 8 days prior to inclusion\n* Infectious episode within 8 days prior to inclusion","0 Months",{"count":125,"type":22},130,[67],"Fever in infants younger than 3 months is a common reason for emergency department visits and is associated with a significant risk of serious bacterial infections. Because it is difficult to distinguish bacterial from viral infections at presentation, management is often aggressive and includes invasive procedures, hospitalization, and empiric antibiotic therapy.\n\nDespite advances in molecular diagnostics, the etiology of fever remains unidentified in a substantial proportion of cases. This study aims to assess the presence of pathogenic viruses in respiratory and intestinal samples from febrile infants younger than 3 months compared with afebrile controls, and to explore associations with clinical, biological, environmental, and socio-economic factors",[29,129,130],"Viral Infection","Bacterial Infections",[132,133,134,135],"fever in infants under 3 months","Viruses","Respiratory infection multiplex PCR","Virome","NOT_YET_RECRUITING","2026-03-16",{"date":139,"type":46},"2026-03-17",{"date":141,"type":22},"2026-04-01",{"date":143,"type":22},"2028-03-31",{"name":145,"class":81},"University Hospital, Montpellier",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":16,"sex":17,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":65,"phases":157,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100605153","phase-4-safety-of-rsv-preventive-monoclonal-antibody-100605153","NCT07158814","Safety of RSV Preventive Monoclonal Antibody","Safety of Simultaneous Administration of Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody With Routine Childhood Immunizations in Infants","Inclusion Criteria:\n\n* Infants ≥ 6 weeks to \\\u003C30 weeks of age at the time of enrollment\n* Infants eligible for RSV monoclonal antibody and at least one routine childhood vaccine in outpatient clinic\n* The parent\u002Flegal guardian must be willing and capable of providing permission for their infant to participate through the written informed consent process\n* Parent\u002Flegal guardian must be able to read and comprehend English or Spanish\n* The parent\u002Flegal guardian must be available for follow-up study contact by telephone from enrollment to completion of the study period\n* The parent\u002Flegal guardian must agree to sign a medical record release for the infant so that study personnel may obtain medical information about the infant's health (if needed)\n* The parent\u002Flegal guardian must be willing to delay their child's receipt of RSV monoclonal antibody up to two weeks from the scheduled date and to return for a second visit to receive the deferred RSV monoclonal antibody\n\nExclusion Criteria:\n\n* Known contraindication or precaution to RSV monoclonal antibody or other routine vaccines being administered\n* Received any vaccine within 14 days prior to enrollment and the first immunization day in this study\n* Known previous receipt of RSV monoclonal antibody\n* Received any experimental\u002Finvestigational agent (vaccine, drug, biologic, device, blood product, or medication) within 28 days prior to immunization in this study or expects to receive an experimental\u002Finvestigational agent within the follow-up time period (8 days after the second immunization in this study)\n* A moderate to severe acute illness and\u002For a reported temporal temperature greater than or equal to 100.4°F (38.0°C) within 48 hours prior to enrollment or a temporal temperature (measured by temporal artery thermometer) greater than or equal to 100.4°F (38.0°C) at the time of enrollment. (This may result in a temporary delay of immunization)\n* Receipt of an antipyretic medication (acetaminophen or ibuprofen) within 48 hours prior to enrollment (This may result in a temporary delay of immunization)\n* Planned receipt of a prophylactic antipyretic medication on the day of and\u002For days following immunization. This exclusion does not apply if the parent\u002Flegal guardian indicates they might administer antipyretics after immunization in response to fever or pain\n* Has any condition that would, in the opinion of the site investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol\n* Anyone who is a first-degree relative of any research study personnel\n* The infant is born to a mother who received a maternal RSV immunization more than 14 days prior to delivery and is not eligible for RSV preventative monoclonal antibody\n* Bleeding disorder or condition associated with prolonged bleeding that would present as a safety risk per opinion of the investigator\n* History of severe adverse reaction associated with a vaccine and\u002For severe allergic reaction to any component of the vaccines or RSV monoclonal antibody\n* Has an active neoplastic disease, or a history of any hematologic malignancy\n* History of a severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of a vaccine administered on the day of study enrollment\n* Immunosuppression as a result of an underlying illness or treatment or use of anti-cancer chemotherapy or radiation therapy since birth\n* For infants receiving DTaP vaccine (alone or combination vaccine): Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures), not attributable to another identifiable cause, within 7 days of administration of previous dose of DTaP\n* Intention to receive non-live or live vaccines during the 4 weeks after Visit 1; vaccines may be administered after enrollment if deemed a personal or public health priority by the health care provider caring for this patient or the study team\n* Long term (at least 14 days of prednisone 2 mg\u002Fkg\u002Fday or equivalent other glucocorticoid) use of any parenteral steroids within the 6 months prior to enrollment (topical, nasal and inhaled steroids are allowed)","6 Weeks","30 Weeks",{"count":156,"type":22},524,[158],"PHASE4","This is a prospective, randomized, open-label clinical trial to evaluate the safety of administration of respiratory syncytial virus (RSV) preventive monoclonal antibody and other routine childhood vaccines given simultaneously at Visit 1, as compared to sequential administration of respiratory syncytial virus (RSV) preventive monoclonal antibody and other vaccines at separate visits (Visits 1 and 2).",[29,161],"Adverse Event Following Immunisation",[163,164,165],"Respiratory Syncytial Virus (RSV)","Fever Following Immunization","RSV Monoclonal Antibody","2026-03-12",{"date":137,"type":46},{"date":169,"type":46},"2025-10-02",{"date":171,"type":22},"2027-04",{"name":173,"class":81},"Duke University",6,{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":182,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":186,"conditions":187,"keywords":190,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":115},"100628560","neuroendocrine-response-in-pediatric-febrile-seizures-100628560","NCT07463222","Neuroendocrine Response in Pediatric Febrile Seizures","Febrile Seizures in Children: Association of Thyroxine (T4), Epinephrine, and Norepinephrine Levels With Seizure Characteristics and Hospital Outcomes-A Prospective Controlled Observational Study","Inclusion Criteria:\n\n* Children aged 6 months to 5 years presenting to the pediatric emergency department with fever (documented at presentation or reported by caregiver within the preceding 24 hours).\n* Case group: febrile seizure occurring in the context of a febrile illness.\n* Control group: febrile illness without seizure, selected to be age-matched to cases (e.g., within ±6 months).\n* Written informed consent obtained from a parent or legal guardian.\n\nExclusion Criteria:\n\n* Suspected or confirmed central nervous system infection (e.g., meningitis, encephalitis).\n* Prior diagnosis of epilepsy or history of afebrile seizures.\n* Seizures attributable to acute metabolic derangements at presentation (e.g., significant hypoglycemia, clinically relevant electrolyte disturbances).\n* Known thyroid disease or use of thyroid hormone\u002Fantithyroid medications.\n* Known adrenal disorders or use of systemic catecholamine infusions at enrollment.\n* Major chronic neurologic disorders or acute head trauma.\n* Inability to obtain blood samples within protocol-defined time windows.","6 Months","5 Years",{"count":185,"type":22},120,"Febrile seizures are the most common seizure type in early childhood and usually occur during febrile illnesses. Although most febrile seizures are benign, the biological stress response during seizures is not fully understood. In particular, changes in thyroid hormones and stress-related hormones released by the sympathetic nervous system may play a role in seizure characteristics and clinical outcomes.\n\nThis prospective observational study aims to evaluate the neuroendocrine response in children presenting with febrile seizures by measuring serum thyroxine (T4), epinephrine, and norepinephrine levels. These measurements will be obtained during the acute phase after seizure cessation and compared with levels measured at recovery and with febrile children without seizures.\n\nThe study will examine the relationship between neuroendocrine marker levels and seizure characteristics such as seizure duration and recurrence, as well as clinical outcomes including length of hospital stay and need for pediatric intensive care unit admission.\n\nBy improving understanding of the hormonal stress response associated with febrile seizures, this study aims to contribute to the knowledge of seizure pathophysiology in childhood and may help identify biological factors associated with more severe clinical courses.",[188,189,29],"Febrile Convulsion","Neuroendocrine Stress Response",[29,191,192,193,194,195,196,197],"Febrile seizure","Neuroendocrine response","Pediatric emergency","Child","Thyroxine","Epinephrine","Norepinephrine","2026-03-05",{"date":200,"type":46},"2026-03-11",{"date":202,"type":22},"2026-03",{"date":204,"type":22},"2027-03",{"name":206,"class":81},"Aydin Adnan Menderes University",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":65,"phases":216,"briefSummary":217,"conditions":218,"keywords":222,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":115},"100626227","assessing-the-effectiveness-of-large-language-model-llm-enabled-nurse-treatment-planning-in-2-indian-districts-100626227","NCT07432893","Assessing the Effectiveness of Large Language Model (LLM)-Enabled Nurse Treatment Planning in 2 Indian Districts","Assessing the Effectiveness of Large Language Model (LLM)-Enabled Nurse Treatment Planning in 2 Indian Districts: A Pilot Study","Inclusion Criteria:\n\n1. Adults aged ≥18 years\n2. Presenting to participating primary care facilities in study sites\n3. Meeting criteria for at least one of the following conditions or symptoms:\n\n   * Hypertension: Known diagnosis\n   * Diabetes mellitus: Known diagnosis or laboratory evidence (HbA1c ≥6.5%, fasting blood glucose ≥126 mg\u002FdL, or post-prandial glucose ≥200 mg\u002FdL)\n   * Fever: Presenting as chief complaint\n   * Breathlessness: Presenting as chief complaint, without evidence of fever\n   * Musculoskeletal pain: Presenting as chief complaint, without evidence of fever\n4. Able and willing to provide written informed consent\n5. Willing to participate in two sequential consultations and complete an exit survey\n\nExclusion Criteria:\n\n1. Inability to provide informed consent due to cognitive impairment (e.g., dementia or intellectual disability)\n2. Medical instability or condition requiring immediate emergency referral\n3. Prior participation in the study during an earlier visit",{"count":215,"type":22},672,[67],"The goal of this clinical trial is to learn whether AI-enabled, nurse-led treatment planning can improve the quality of clinical reasoning and management compared with standard physician-led care in adult primary care patients (≥18 years) presenting with hypertension, diabetes mellitus, fever, breathlessness, or musculoskeletal pain in rural and semi-urban India.\n\nThe main questions it aims to answer are:\n\n* Does a nurse + large language model (LLM) consultation achieve non-inferior clinical quality scores compared with a standard doctor consultation?\n* Is AI-assisted nurse-led care acceptable and satisfactory to patients in primary healthcare settings? Researchers will compare nurse + LLM-led consultations with physician-led standard-of-care consultations within the same participant to see if the AI-enabled nurse model delivers comparable or improved clinical reasoning and treatment planning.\n\nParticipants will:\n\n* Receive two sequential consultations for the same visit (one with a nurse using an AI tool and one with a physician, order randomized).\n* Have both consultations audio recorded for blinded clinical quality assessment.\n* Complete a brief exit survey on communication, trust, and satisfaction after the AI-assisted nurse consultation.",[219,220,221,29],"Hypertension","Diabete Mellitus","Breathlessness",[223,224,225,226,227],"Artificial Intelligence","Delivery of Health Care","Health Personnel","Frontline Workers","Resource-Limited Settings","2026-02-19",{"date":230,"type":46},"2026-02-25",{"date":232,"type":46},"2026-01-13",{"date":234,"type":22},"2026-07-31",{"name":236,"class":81},"Sarah Nabia",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":17,"minAge":182,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":65,"phases":247,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":115},"100625754","antipyretic-therapy-with-and-without-cold-sponging-100625754","NCT07426744","Antipyretic Therapy With and Without Cold Sponging","Antipyretic Therapy With and Without Cold Sponging: A Comparative Study in Febrile Children.","Inclusion Criteria:\n\n* Children of either gender\n* Aged 6 to 60 months.\n* Presenting with a fever (an axillary or oral temperature \\>38.0°C)\n* No use of paracetamol or other antipyretics within the past 6 hours. 4. Parental\u002Fguardian giving informed written consent.\n\nExclusion Criteria:\n\n* Children with chronic systematic conditions (e.g., congenital heart defects, renal or respiratory diseases)\n* History of febrile seizures or other seizure disorders\n* Known hypersensitivity or contraindication to paracetamol\n* Presence of dermatological conditions that may aggravate by sponging (eg., eczema, contact dermatitis, psoriasis, skin infection, xerosis)","60 Months",{"count":246,"type":22},210,[67],"This study aims to fill the gaps regarding the effectiveness of paracetamol alone with paracetamol combined with cold sponging in febrile children.",[29],"2026-02-16",{"date":252,"type":46},"2026-02-23",{"date":254,"type":22},"2026-03-01",{"date":256,"type":22},"2026-08-31",{"name":258,"class":81},"Muhammad Aamir Latif",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":115},"100550458","continuos-body-temperature-monitoring-100550458","NCT06447337","Continuos Body Temperature Monitoring","Examination of a Telemedicine System for Continuous Monitoring of Body Temperature in Adults - a Pilot Study","Inclusion Criteria:\n\n* A person of male or female sex\n* Age 18 and over\n* Ability to measure the patient's body temperature frequently\n* People who are hospitalized due to any type of infection or any other diseases that result in variations in body temperature (rise, fall)\n* Completed all potential diagnostics of the hospitalized patient (no interrupting the measurement of the telemedicine device)\n\nExclusion Criteria:\n\n* Allergic to contact with plastic or silver\n* Anatomical anomalies that prevent the placement of the system\n* High-risk health conditions, intensive care and the like\n* A pacemaker or other device on the skin or implanted in the body that emits light electromagnetic radiation",{"count":267,"type":22},40,"This is a nonrandomized, diagnostic, single-center, pilot study, with one group of participants. The aim is to examine the effectiveness and safety of telemedicine system for continuous measurement of body temperature in adults. Up to 40 subjects will participate in this phase of the clinical trial. No stratification, nor randomization of subjects will be performed. Respondents who meet the inclusion criteria will be monitored for up to 72 hours plus 72 hours after removing the device. Namely, the device will be placed on their body and will be there until upt to 72 hours, and then it will be removed. The respondent will be monitored by the team for an additional 72 hours by the person in charge of the examination, for possible side effects.\n\nSensor will be placed in the axilar joint or a little below on the side. The device will be connected to a mobile phone. Member of the research team (principal researcher\u002Fco-researcher\u002F nurse in charge of examination) measures the temperature of the skin in the opposite armpit manually, ie with a gallium thermometer and records every 30-60 minutes. When body temperature starts to rise, a member of the research team measures the body temperature every 15-30 minutes. After reaching a stable temperature, the temperature is measured every 30-60 minutes. If the subject is given drugs to lower body temperature, the temperature is measured again every 15-30 minutes until the temperature stabilizes to a normal subfebrile state.",[29],"2026-01-27",{"date":272,"type":46},"2026-01-28",{"date":274,"type":46},"2024-12-16",{"date":276,"type":22},"2026-07-30",{"name":278,"class":279},"Baby FM Doo","INDUSTRY",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":65,"phases":290,"briefSummary":291,"conditions":292,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":115},"100610760","sulfamethoxazole-prophylaxis-duration-after-renal-transplantation-100610760","NCT07231770","Sulfamethoxazole Prophylaxis Duration After Renal Transplantation","A Controlled Study on the Prophylaxis of Pneumocystis Jirovecii Pneumonia With Fixed-dose Compound Sulfamethoxazole Tablets of Different Maintenance Durations After Renal Transplantation","SPDART","Diagnostic Criteria for PJP (meeting one of the following criteria is sufficient):\n\n1. Detection of Pneumocystis jirovecii via sputum Gomori methenamine silver (GMS) stain.\n2. According to guidelines\u002Fconsensus: Positive direct immunofluorescence assay and\u002For positive polymerase chain reaction (PCR) assay on induced sputum or bronchoalveolar lavage fluid (BALF) specimens.\n3. Detection of Pneumocystis jirovecii strains in sputum, blood, or bronchoalveolar lavage fluid (BALF) by metagenomic next-generation sequencing (mNGS).\n\nInclusion Criteria:\n\n* Subjects must meet all the following conditions to be enrolled: (1) Age: 18-70 years old; (2) Post-renal transplantation; (3) Voluntarily participate in this clinical study, be able to cooperate with researchers to conduct the study, and sign the informed consent form.\n\nExclusion Criteria:\n\n* Criteria: Subjects with any of the following conditions shall be excluded from the trial: (1) HIV-positive; (2) History of TMP-SMX allergy; (3) Glucose-6-phosphate dehydrogenase (G6PD) deficiency; (4) Megaloblastic anemia; (5) Multiorgan transplantation; (6) Complicated with tumor; (7) Complicated with connective tissue disease; (8) Pregnant patients.",{"count":289,"type":22},450,[67],"Renal transplantation is the most ideal and effective treatment for end-stage renal disease. Pneumocystis jirovecii pneumonia (PJP) is one of the most common pulmonary infections after renal transplantation, with high morbidity and mortality that seriously affects patients' prognosis and survival. PJP can be prevented with drugs, and trimethoprim-sulfamethoxazole (TMP-SMX) is the first-choice prophylactic agent. However, there is no clear definition of the prophylactic course of TMP-SMX in domestic and international guidelines. Most of the prophylactic durations for PJP are based on the clinical experience of physicians, ranging from 6 to 12 months across different transplant centers. Multiple studies have shown that some patients still develop PJP more than one year after renal transplantation. Previous research by our team found that PJP has a peak incidence around 9 months after renal transplantation, with a second peak occurring between 10 and 15 months. This study aims to adopt a single-center, randomized, parallel-controlled trial design, planning to enroll 450 patients after renal transplantation. It will investigate the impact of different prophylactic courses of TMP-SMX on the incidence of PJP, and explore whether long-term prophylaxis is more reasonable and effective than short-term prophylaxis. Meanwhile, during follow-up, the peak serum concentration of SMZ in patients will be measured to analyze the relationship between SMZ serum concentration and the occurrence of PJP as well as adverse reactions. A clinical prediction model will be constructed to reveal the effective concentration range of TMP-SMX for prophylactic use. This will further optimize the prophylactic regimen, provide practical guidance for clinical practice, reduce the morbidity and mortality of PJP, and improve prognosis.",[29,293],"Chest Tightness","2025-12-15",{"date":296,"type":46},"2025-12-16",{"date":298,"type":46},"2024-05-28",{"date":300,"type":22},"2027-08-08",{"name":302,"class":303},"Anhui Provincial Hospital","OTHER_GOV",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":310,"minAge":91,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":65,"phases":313,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":328},"100568529","the-impact-of-local-anesthetic-solution-temperature-on-epidural-related-maternal-fever-100568529","NCT06682416","The Impact of Local Anesthetic Solution Temperature on Epidural-related Maternal Fever","Inclusion Criteria:\n\n1. Requesting epidural analgesia;\n2. Aged 18 or older;\n3. At least 37 weeks of gestation;\n4. Those delivering vaginally.\n\nExclusion Criteria:\n\n1. Contraindications to epidural analgesia;\n2. Pre-existing fever (≥38°C) before labor;\n3. Use of NSAIDs or other types of antipyretics before labor;\n4. Multiple pregnancy (carrying more than one fetus);\n5. Fetal demise (stillbirth);\n6. Severe preeclampsia;\n7. Women who refuse to participate.","FEMALE",{"count":312,"type":22},424,[67],"This study investigates how the temperature of local anesthetics affects maternal fever related to epidural analgesia during childbirth. The research is a prospective, randomized controlled trial involving 424 participants from two hospitals. The primary objective is to investigate the impact of local anesthetic solution temperature on intrapartum fever in parturients. Secondary goals include assessing the impact on the efficacy of epidural analgesia and various maternal and neonatal outcomes. Participants will receive either 37°C or 23°C anesthetic solutions, and data will be collected on fever rates, pain scores, and other health indicators. The study runs from January 2024 to December 2026.",[316,317,29,318],"Epidural Related Maternal Fever","Analgesia, Epidural","Intrapartum Fever","2025-09-10",{"date":321,"type":46},"2025-09-11",{"date":323,"type":46},"2024-11-30",{"date":325,"type":22},"2027-10-01",{"name":327,"class":81},"The First Affiliated Hospital of Soochow University",2,{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":17,"minAge":182,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":65,"phases":338,"briefSummary":339,"conditions":340,"keywords":341,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":115},"100598701","prescription-antipyretics-to-decrease-unscheduled-return-visits-in-a-pediatric-emergency-department-100598701","NCT07074912","Prescription Antipyretics to Decrease Unscheduled Return Visits In A Pediatric Emergency Department","Inclusion Criteria:\n\n* Children 6 to \\\u003C 36 months of age being discharged home from Dell Children's Medical Center emergency department who are evaluated for fever\n* Caregiver fluent in English or Spanish\n\nExclusion Criteria:\n\n* Previous enrollment in this study\n* Patient admitted to hospital\n* Parental request for a prescription for acetaminophen and\u002For ibuprofen\n* Trauma patient\n* Orthopedic complaint\n* Other painful indication for acetaminophen or ibuprofen\n* Acetaminophen or ibuprofen prescribed for anything other than fever\n* Allergy or another contraindication to acetaminophen or ibuprofen\n* Parent and patient unlikely to follow up in the region (i.e., lives out of state)","36 Months",{"count":337,"type":22},440,[67],"The study aims to evaluate whether unscheduled return visits within one week for similar complaints are impacted by ensuring parents leave the emergency department (ED) with a prescription for appropriately dosed acetaminophen and ibuprofen for their child.",[29],[342,343,344],"emergency department","fever","pediatrics","2025-07-10",{"date":347,"type":46},"2025-07-20",{"date":349,"type":46},"2024-12-15",{"date":351,"type":22},"2026-03-15",{"name":353,"class":81},"University of Texas at Austin",{"id":355,"slug":356,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":16,"sex":17,"minAge":91,"maxAge":362,"enrollmentInfo":363,"targetDuration":365,"studyType":23,"phases":4,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":375,"leadSponsor":377,"locationsCount":115},"100591522","caspase-1-activity-il-1beta-and-il-18-in-patients-with-fmf-100591522","NCT06981520","Caspase-1 Activity, IL-1beta, and IL-18 in Patients With FMF","Effect of Caspase-1 Activity, IL-1beta, and IL-18 on Inflammation in the Mucosa of the Small Intestine of Patients With FMF","FMF","Inclusion Criteria:Age 18 years or older\n\nConfirmed diagnosis of Familial Mediterranean Fever (FMF) according to Tel-Hashomer clinical criteria and\u002For MEFV gene mutation analysis (for FMF group)\n\nUndergoing routine endoscopy with mucosal biopsy sampling\n\nAvailability of sufficient formalin-fixed paraffin-embedded (FFPE) tissue for immunohistochemical analysis\n\nFor controls: absence of systemic inflammatory or autoimmune disease -\n\nExclusion Criteria:History of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)\n\nCurrent use of immunosuppressive therapy (excluding colchicine)\n\nSevere infection, active malignancy, or other systemic disease affecting intestinal mucosa\n\nInadequate biopsy specimen quality for histopathological evaluation\n\n\\-","55 Years",{"count":364,"type":22},30,"8 Months","This study aims to investigate the intestinal mucosal expression of key inflammatory markers, namely Interleukin-1 (IL-1), Interleukin-18 (IL-18), and Caspase-1, in patients with Familial Mediterranean Fever (FMF). FMF is an autoinflammatory disorder characterized by recurrent episodes of fever and serosal inflammation. Recent studies suggest a possible role of intestinal immune activation in the disease pathogenesis, particularly through inflammasome-related cytokines. To better understand mucosal involvement in FMF, immunohistochemical staining for IL-1, IL-18, and Caspase-1 will be performed on intestinal biopsy samples obtained during routine endoscopic procedures. The staining intensity and distribution patterns will be evaluated and compared with age- and sex-matched healthy controls. The findings may help clarify mucosal inflammatory pathways involved in FMF and provide insight into novel therapeutic targets.",[368,369,370,29],"Familial Mediterranean Fever","Intestinal Disease","Genetic Disease","2025-05-13",{"date":373,"type":46},"2025-05-20",{"date":345,"type":22},{"date":376,"type":22},"2026-01-19",{"name":378,"class":81},"Hitit University",{"id":380,"slug":381,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":16,"sex":17,"minAge":387,"maxAge":388,"enrollmentInfo":389,"targetDuration":391,"studyType":23,"phases":4,"briefSummary":392,"conditions":393,"keywords":398,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":115},"100429936","transcriptomic-responses-for-the-identification-of-pathogens-100429936","NCT04878549","Transcriptomic Responses for the Identification of Pathogens","A Multisite Evaluation of Functional Genomic Signatures for the Improved Diagnosis of Acute Undifferentiated Febrile Infections","TRiP","FEBRILE ADULTS- INCLUSION CRITERIA\n\n* Age greater than or equal to 15 years and less than or equal to 65 years\n* Participant is willing and they and\u002For an appropriate guardian\u002Frelative\u002Frepresentative is able to give informed consent for participation in the study and a follow-up (telephone) discussion at 14 days\n* And either:\n\n  1. Febrile illness without localising features (see 'exclusion criteria' and 'screening' sections) where fever is defined as:\n\n     * documented tympanic\u002Frectal temperature of ≥ 38°C or an axillary\u002Foral temperature of ≥ 37.8°C, or a reported fever within the last 24 hours and\n     * Reported duration of fever 3-14 days or\n  2. Recently confirmed blood culture indicating enteric fever (confirmed within the previous 5 days)\n* They may have had recent exposure to antimicrobials.\n\nFEBRILE ADULTS- EXCLUSION CRITERIA\n\n* The participant may not enter the study if ANY of the following apply:\n* Unable to provide informed consent and no next of kin is willing and able to provide informed consent.\n* For patients with febrile illness (included in (1) above): Any history or clinical suspicion of:\n\n  * Rheumatological or connective tissue disorder (e.g. Rheumatoid arthritis)\n  * Autoimmune condition (e.g. Autoimmune Hepatitis)\n  * Malignancy\n  * Active treatment with immunomodulating medications, or for tuberculosis (pulmonary or extrapulmonary) or any other chronic infection.\n* Pregnancy (breast feeding mothers will NOT be excluded)\n* No hospitalisation for more than 48 hours in the last 4 weeks\n* Vaccination within 4 weeks prior to current admission\n* Localising signs or symptoms of infection sufficient to diagnose the likely cause of acute febrile illness and thus prevent it from being 'undifferentiated.'\n\nCONTROLS- INCLUSION CRITERIA\n\n* Participant is willing and they are (and in 15-18 year olds, a guardian is) able to give informed consent for participation in the study\n* Age greater than or equal to 15 years and less than or equal to 65 years\n* They live outside of the normal\u002Flocal catchment area for each hospital site\n* Afebrile (as defined by no reported fever and temperature ≤ 38°C or an axillary\u002Foral temperature of ≤ 37.8°C).\n\nCONTROLS- EXCLUSION CRITERIA\n\n* The participant may not enter the study if ANY of the following apply:\n* Unable to provide informed consent and no next of kin (or parent\u002Fguardian in the case of a minor) is willing and able to provide informed consent.\n* Current treatment for or prior history, or clinical suspicion of:\n\n  * Rheumatological or connective tissue disorder\n  * Autoimmune condition\n  * Malignancy\n  * Active treatment for tuberculosis (pulmonary or extrapulmonary) or clinical suspicion of active tuberculosis. Previous completed treatment is not a reason for exclusion.\n  * Active treatment with immunomodulating medications or any other chronic infection.\n* Pregnant (breast feeding mothers will NOT be excluded)\n* Hospitalisation within 4 weeks of recruitment\n* Vaccination within 4 weeks prior to recruitment\n* Antimicrobial use within 4 weeks of recruitment\n* Participant reports feeling more unwell than usual on the day of enrolment.\n\nEXPLORATORY AIMS- PAEDIATRIC CRITERIA; INCLUSION CRITERIA\n\n* Age greater than or equal to 2 years and less than 15 years\n* As above for adult participants.\n\nEXPLORATORY AIMS- PAEDIATRIC CRITERIA; EXCLUSION CRITERIA\n\n* Parent\u002Fguardian is unwilling, and\u002For patient aged 8 to 14 years is unwilling to assent to provide informed consent.\n* As above for adult participants.","2 Years","65 Years",{"count":390,"type":22},2000,"14 Days","Acute undifferentiated febrile infection (AUFI) is a common presenting syndrome in low-resource settings and better diagnostics are urgently needed to improve patient management and guide disease prevention interventions. Assessment of the host gene expression response to infection in endemic populations has demonstrated significant promise as a new approach to identifying patients with enteric fever and for potential in differentiating between other causes of AUFI. Signatures identified through new data analytic techniques could be developed into a point-of-care test for use in endemic settings.\n\nIn this multisite diagnostic evaluation study we will collect prospective clinical, laboratory and diagnostic data from two endemic settings to evaluate host gene expression signatures for detecting enteric fever and for determining the cause of AUFI in LMIC settings.",[394,395,396,397,29],"Enteric Fever","Acute Febrile Illness","Typhoid","Paratyphoid Fever",[399,400],"Gene Expression Profiling","RNA-Seq","2025-02-26",{"date":403,"type":46},"2025-03-03",{"date":405,"type":46},"2022-05-02",{"date":407,"type":22},"2025-06",{"name":409,"class":81},"University of Sheffield",{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":65,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":328},"100565109","triverity-for-improved-management-of-emergency-department-ed-patients-with-suspected-infections-100565109","NCT06637904","TriVerity™ for Improved Management of Emergency Department (ED) Patients With Suspected Infections","TIMED","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Participant presents to ED with ALL of the below:\n\n   2.1. Suspected acute infection (e.g., respiratory, urinary, abdominal, skin \\& soft-tissue infection, meningitis\u002Fencephalitis, or any other infection), and 2.2. Either heart rate \\>100 beats per minute or\u002Fand temperature \\>38C. 2.3. NOT immediately roomed in a primary designated treatment location,( i.e., they can be in the waiting room, ED triage hallways, and\u002For ED staging area\u002Ffast track area).\n3. Able to provide informed consent, or consent by legally authorized representative.\n4. Reachable via confirmed working cell phone (with backup contact number) and willing to respond to follow-up safety checks (see below for details).\n\nExclusion Criteria:\n\n1. Patient-reported treatment with systemic antibiotics, systemic antiviral agents or systemic antifungal agents within the past 7 days prior to presentation in the waiting room of the ED. Participants will not be excluded for use of:\n\n   1. Antiviral treatment for chronic viral infections, i.e., HIV, hepatitis B and hepatitis C\n   2. Topical antibiotics, topical antivirals or topical antifungal agents\n   3. Anti-herpes prophylaxis aiding suppression of a recuring herpes infection\n   4. Single dose of one or combination of peri-operative (prophylactic) antibiotics\n2. Patients receiving palliative or hospice care, or those receiving limited interventional care (see Appendix B).\n3. Prisoners, mentally disabled, or unable to give consent. Should the patient not be able to provide informed consent the legally authorized representative can provide the consent on behalf of the patient.\n4. Participants receiving experimental therapy or already enrolled in an interventional clinical trial in which a subject receives some type of intervention, which can include but is not limited to investigational drugs, medical devices, or vaccines. Participants that are enrolled in non-interventional or observational clinical trials will be allowed to participate in this clinical trial.\n5. Participants previously enrolled in the present clinical trial.",{"count":418,"type":22},300,[67],"A pre\u002Fpost interventional use trial, with ED patients who are initially triaged to locations other than a dedicated patient room in the main ED (e.g., waiting room, hallway bed, and\u002For the staging area\u002Ffast track area) with suspected infection and tachycardia or fever will be enrolled. Study conduct will be performed under an Investigational Device Exemption (IDE) from the Food and Drug Administration (FDA). Participants in the pre-phase, treated with standard of care, will be gathered from a retrospective database using propensity matching, whereas participants in the post-phase will be managed incorporating the TriVerity™ Acute Infection and Sepsis Test results with standardized guidance for interpretation and resulting management actions. Many outcomes will be captured and compared between the pre- and post-phase phases including sepsis bundle compliance, patient disposition, appropriate use of antimicrobials (antibiotics and antivirals) and health economic findings. Safety measures for participants in the post-phase will include patient follow-up at predefined time points. The objective is to demonstrate improvement of patient management when incorporating the TriVerity Test result compared to standard of care. Improvements based on diagnostic (bacterial vs viral vs non-infectious inflammation) and prognostic (need for 7-day ICU level care) readouts of the TriVerity Test result will be tracked.",[422,423,424,29],"Sepsis","Infections","Tachycardia","2025-01-06",{"date":427,"type":46},"2025-01-08",{"date":429,"type":46},"2024-11-08",{"date":431,"type":22},"2025-03-31",{"name":433,"class":279},"Inflammatix",{"id":435,"slug":436,"hasResults":11,"nctId":437,"briefTitle":438,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":65,"phases":442,"briefSummary":443,"conditions":444,"keywords":447,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":115},"100573917","remote-temperature-monitoring-of-patients-at-risk-for-developing-fever-100573917","NCT06752512","Remote Temperature Monitoring of Patients At Risk for Developing Fever","Inclusion Criteria:\n\n* Subject is at risk of a fever post discharge.\n* Subject is ≥ 18 years or older.\n* Subject has an iOS or Android phone, or is able to operate an AION provided smartphone device.\n* Subject is willing to install the TempShield app on his\u002Fher phone.\n* Subject is willing to allow AION to send text reminders to take temperature or complete surveys.\n* Subject is willing to take an oral temperature as directed by their care plan.\n* Subject is willing to configure the phone to ensure these notifications are delivered, even when phone is in a \"no notification\" mode.\n* Subject or subject caretaker is able and willing to complete subject surveys.\n* Subject is willing and able to provide written informed consent in English.\n* Subject is willing and able to comply with all program procedures, requirements, assessments, visits, and complete questionnaires.\n* English speakers\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Subjects with a history of Medical Adhesive-Related Skin Injury (MARSI)\n* Subjects with no available placement that avoids open wounds or traumatized skin (burns. Blisters. Etc.)\n* Non-English speakers: The mobile application is only currently available in English. Future development will include other languages.\n* Subjects receiving prophylactics that could induce fever.\n* Subjects with a silicon allergy\n* Subject does not have iOS or Android phone, and is unable to operate an AION provided smartphone device.\n* Subjects who are not willing to take an oral temperature per their care plan.",{"count":441,"type":22},150,[67],"The purpose of this program is to evaluate remote temperature monitoring in cancer patients at risk of fever and infection due to chemotherapy treatment. The main questions it aims to answer are:\n\n* does remote temperature monitoring reduce the number of days spent inpatient\n* what out-of-pocket cost can a patient expect to incur for participating in remote temperature monitoring\n* the number of billable CPT codes that will be generated by providing remote temperature monitoring\n\nResearchers will compare compliant and non-compliant patients to assess if compliance with remote temperature monitoring is associated with a decrease in the number of days spent inpatient.\n\nPatients will\n\n* wear the thermometer for the duration of their participation in the study\n* have their temperature monitored continuously\n* receive alerts on their phone when their temperature exceeds a threshold for a sustained duration, configurable by their physician\n* respond to texts or calls from remote monitors when an alert is triggered",[29,445,446],"Cancer","Remote Patient Monitoring",[343,448,449,450,451,452,453,454,455],"infection","sepsis","cancer","chemotherapy","immunocompromised","temperature","wearable","remote patient monitoring","2024-12-22",{"date":458,"type":46},"2024-12-30",{"date":460,"type":46},"2023-08-09",{"date":462,"type":22},"2025-01",{"name":464,"class":279},"AION Biosystems",{"id":466,"slug":467,"hasResults":11,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":65,"phases":474,"briefSummary":475,"conditions":476,"keywords":477,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":491},"100562183","fever-education-given-to-parents-of-children-presenting-to-the-emergency-department-with-fever-100562183","NCT06599853","Fever Education Given to Parents of Children Presenting to the Emergency Department With Fever","Evaluation of the Effect of Fever Education Given to Parents of Children Presenting to the Emergency Department With Fever on Parental Anxiety Level and Fever Management","Inclusion Criteria:\n\n* Having a child between the ages of 1-5\n* Able to read, understand and have no problems speaking Turkish\n* Having a green triage code in the emergency room triage application\n\nExclusion Criteria:\n\n* Children diagnosed with or receiving treatment for chronic diseases\n* Children with a history of febrile convulsions\n* Children dependent on home mechanical ventilation\n* Parents with psychiatric diagnoses will be excluded from the study",{"count":473,"type":22},80,[67],"Fever is a common symptom of childhood, especially between the ages of one and five, and is the main reason for emergency room visits. These emergency room visits are due to parents incorrect information and practices regarding fever management. This situation causes an increase in parental anxiety and failure to provide fever management. In line with this information, this study was planned to evaluate the effects of education given to parents of children presenting to the emergency room with fever on parental anxiety level and fever management.",[29],[478,29,479,480,194,481],"Emergency","Parents","Education","Anxiety","2024-09-17",{"date":484,"type":46},"2024-09-19",{"date":486,"type":46},"2024-04-01",{"date":488,"type":22},"2025-11-01",{"name":490,"class":81},"Merve YETİMOĞLU",3,{"id":493,"slug":494,"hasResults":11,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":498,"eligibilityCriteria":499,"healthyVolunteers":16,"sex":310,"minAge":91,"maxAge":500,"enrollmentInfo":501,"targetDuration":4,"studyType":65,"phases":503,"briefSummary":504,"conditions":505,"keywords":507,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":115},"100543339","phase-4-effect-of-intravenous-vitamin-c-on-intrapartum-maternal-fever-after-epidural-labor-analgesia-100543339","NCT06354582","Effect of Intravenous Vitamin C on Intrapartum Maternal Fever After Epidural Labor Analgesia","Effect of Intravenous Vitamin C on Intrapartum Maternal Fever After Epidural Labor Analgesia : A Randomized Controlled Trial","EIVCIMFAELA","Inclusion Criteria:\n\n* single-fetus, head position, and full-term vaginal delivery receiving epidural labor analgesia.\n\nExclusion Criteria:\n\n* have a fever before epidural analgesia, acute infection on admission, incomplete baseline data, fatal fetal malformations or comorbidities, duration from admission to delivery of more than 72 hours or less than 3 hours, or an American Society of Anesthesiologists (ASA) classification of ≥ Ⅲ.","35 Years",{"count":502,"type":22},400,[158],"This study aims to explore the effect of intravenous vitamin C infusion on intrapartum fever after epidural labor analgesia, to reduce the impact of intrapartum fever on maternal and infant, improve maternal and infant outcomes, and provide a reference for clinical preventive medication.",[506,29],"Obstetric Labor Complications",[508,509,510,511],"Intrapartum maternal fever","Epidural analgesia","Inflammation","Vitamin C","2024-06-30",{"date":514,"type":46},"2024-07-03",{"date":516,"type":46},"2024-04-15",{"date":518,"type":22},"2024-10",{"name":520,"class":81},"Kunyue Li",{"id":522,"slug":523,"hasResults":11,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":4,"eligibilityCriteria":527,"healthyVolunteers":11,"sex":17,"minAge":528,"maxAge":529,"enrollmentInfo":530,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":532,"conditions":533,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":115},"100471728","observational-study-about-in-patients-admitted-with-fever-100471728","NCT05422651","Observational Study About In-patients Admitted With Fever","Characteristic, Diagnosis and Prognosis of Patients Admitted With Fever in Department of Infectious Diseases","Inclusion Criteria:\n\n* all patients admitted to department of infectious diseases because of fever\n\nExclusion Criteria:\n\n* patents who refuse to sign informed consent","14 Years","90 Years",{"count":531,"type":22},500,"Fever is a common symptom in patients with infectious diseases. This study hopes to understand the epidemiological characteristics of patients hospitalized due to fever through observational research, including: clinical characteristics, etiology of fever and prognosis after treatment. So as to further search for biochemical or other serological indicators to predict the diagnosis and prognosis of infectious fever and non-infectious fever, and try to establish relevant prediction models.",[29],"2022-06-23",{"date":536,"type":46},"2022-06-29",{"date":538,"type":46},"2022-06-01",{"date":540,"type":22},"2026-08-01",{"name":542,"class":81},"Xiangya Hospital of Central South University",{"id":544,"slug":545,"hasResults":11,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":549,"eligibilityCriteria":550,"healthyVolunteers":11,"sex":17,"minAge":551,"maxAge":552,"enrollmentInfo":553,"targetDuration":4,"studyType":65,"phases":554,"briefSummary":555,"conditions":556,"keywords":559,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":115},"100373296","phase-4-antibiotic-prophylaxis-in-patients-undergoing-gvo-100373296","NCT04140578","Antibiotic Prophylaxis in Patients Undergoing GVO","Antibiotic Prophylaxis in Patients Undergoing Endoscopic Injection of Cyanoacrylate for Primary and Secondary Prevention of Gastric Variceal Bleeding","ABX-GV","Inclusion Criteria:\n\n1. Patients with live cirrhosis and\u002For hepatoma\n2. Aged 20 to 85, who had endoscopy-treatment EV(-)GV(+)or EV\\\u003CGV\n\nExclusion Criteria:\n\n1. Had a terminal illness of any major organ system,such as heart failure, kindey failure,COPD\n2. Patients recieve antibiotics recently.\n3. Patients suspected infection.","20 Years","85 Years",{"count":441,"type":22},[158],"We design a randomized trial to clarify the necessity of antibiotic prophylaxis for the patients chronic liver disease with gastric varices treated by elective GVO.",[557,422,558,29],"Gastric Varix","Liver Cirrhoses",[560,422,561],"Gastric variceal rebleeding","cyanoacrylate injection","2019-10-24",{"date":564,"type":46},"2019-10-28",{"date":566,"type":46},"2017-01-28",{"date":568,"type":22},"2030-12-31",{"name":570,"class":303},"Taipei Veterans General Hospital, Taiwan"]